Dr. Perales on Remaining Questions With CAR T-Cell Therapy in Hematologic Malignancies

Miguel-Angel Perales, MD
Published: Saturday, Jun 24, 2017



Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses the remaining questions with chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Perales explains that one of the remaining questions with this therapy is regarding multiple drugs being approved in the same indication.

For example, the data coming out of the Kite Pharma, Novartis, and Juno trials in lymphoma look very similar, says Perales. Response rates in all 3 trials come in around 40% to 50%.
 


Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses the remaining questions with chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Perales explains that one of the remaining questions with this therapy is regarding multiple drugs being approved in the same indication.

For example, the data coming out of the Kite Pharma, Novartis, and Juno trials in lymphoma look very similar, says Perales. Response rates in all 3 trials come in around 40% to 50%.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Oncology Briefings™: Updates in Rare Hematology: Advancing Care and Improving Outcomes for Patients with Aplastic AnemiaAug 31, 20181.0
Publication Bottom Border
Border Publication
x